The IJTLD
The IJTLD is the leading peer-reviewed journal dedicated to lung health worldwide.
We welcome submissions on basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
Public Health Action
Public Health Action aims to disseminate the latest operational research on health systems, public health and disease control.
We have recently expanded the scope of PHA to provide coverage of relevant areas of the UN's Sustainable Development Goals (SDGs).
IJTLD Open
Launched in January 2024, IJTLD Open is The Union's new Open Access journal for the latest research on TB and lung diseases including asthma, COVID-19 and COPD.
We welcome submissions on the development of diagnostics and treatments for the prevention, management and control of respiratory diseases.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Conflation of prediction and causality in the TB literature
A forthcoming IJTLD OPEN article addresses the frequent conflation of prediction and causal inference in observational TB studies, and outlines practical recommendations to enhance research precision and transparency.
The rationale for cancer to be made a notifiable disease in India
In this Short Communication (to be published in the Q2 issue of PHA), the authors explain why the Ministry of Health in India should make cancer a notifiable disease.
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, we present an article that assesses the burden of multimorbidity and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe
Evaluating disability, comorbidities and risk factors after TB treatment: an 18–24 month follow-up in China
Ahead of World TB Day, we present an article that assesses disability, comorbidities and risk factors after TB treatment in China.